PanTera, a Belgian joint venture created by IBA and SCK CEN to secure large-scale production of alpha-emitting radioisotopes, has signed a capacity reservation agreement with Bayer for the supply of actinium-225 ( 225Ac) starting in the second half of 2024.   This first agreement with a major drug developer reflects PanTera’s position to be a reliable, EU-based supplier of 225Ac from this year onward. In 2024, PanTera will continue to work on increasing access to 225Ac for clinical trial needs...